Biotech Startups
Funding, biotech venture and emerging labs.
mRNA Is Not a One-Hit Wonder: The Vaccine Platform Era
After COVID, mRNA hit a research wall. Now the platform is back with a pipeline of cancer, RSV and personalised shots.
CRISPR Is Quietly Becoming a Cure Business
Gene editing moved from headlines to clinics: first approved therapies, then a queue of rare-disease cures.
AI Drug Discovery Passed Its First Real Clinical Test
The first molecules designed end-to-end by AI have entered the clinic. Early results vindicate the hype — partly.
The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early
A decade after the first commercial ctDNA tests, blood-based screening is approaching the sensitivity to catch stage I cancer.
GLP-1 Drugs Are Rewriting the Food and Pharma Industries
Obesity drugs moved from niche to blockbuster, and every adjacent industry is scrambling to adjust.
The Epigenetic Clock: Can We Actually Measure Aging?
DNA-methylation clocks claim to tell your biological age to the month. Longevity labs are betting billions on them.
Continuous Glucose Monitors Are Coming for Healthy People
CGM patches moved from diabetics to biohackers to the mass market, and food companies are listening.
CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing
Allogeneic CAR-T therapies aim to replace six-figure bespoke cell production with off-the-shelf donor lines.
Antibiotic Resistance Is the Quiet Public-Health Emergency
Resistant infections kill more people yearly than road accidents, and the R&D pipeline for new antibiotics is nearly empty.
Brain-Computer Interfaces Leave the Lab — Slowly
Neural implants restored movement for paralysed patients. The next battle is commercial, not scientific.